{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:25:54Z","timestamp":1788297954583,"version":"build-2803163510"},"reference-count":36,"publisher":"BMJ","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj-2022-071467","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T06:45:26Z","timestamp":1660632326000},"page":"e071467","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Is daily supervised buprenorphine-naloxone dosing necessary?"],"prefix":"10.1136","volume":"378","author":[{"given":"Robert A","family":"Kleinman","sequence":"first","affiliation":[{"name":"Centre for Addiction and Mental Health, Toronto, ON, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, MA, USA"},{"name":"Department of Psychiatry, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"2025110102021857000_378.aug16_2.e071467.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32229-9"},{"key":"2025110102021857000_378.aug16_2.e071467.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"2025110102021857000_378.aug16_2.e071467.3","unstructured":"Public Health England. COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol. 2020. https:\/\/web.archive.org\/web\/20200510050653\/https:\/\/www.gov.uk\/government\/publications\/covid-19-guidance-for-commissioners-and-providers-of-services-for-people-who-use-drugs-or-alcohol\/covid-19-guidance-for-commissioners-and-providers-of-services-for-people-who-use-drugs-or-alcohol"},{"key":"2025110102021857000_378.aug16_2.e071467.4","unstructured":"Lam V, Sankey C, Wyman J, Zhang M. Covid-19 opioid agonist treatment guidance. 2021. https:\/\/www.camh.ca\/\/-\/media\/files\/covid-19-modifications-to-opioid-agonist-treatment-delivery-pdf.pdf?la=en&hash=261C3637119447097629A014996C3C422AD5DB05"},{"key":"2025110102021857000_378.aug16_2.e071467.5","doi-asserted-by":"publisher","DOI":"10.1080\/10550490490440780"},{"key":"2025110102021857000_378.aug16_2.e071467.6","doi-asserted-by":"publisher","DOI":"10.1080\/10550490490440780"},{"key":"2025110102021857000_378.aug16_2.e071467.7","unstructured":"Levin C. Statement of Hon Carl Levin, A United States senator from the State of Michigan. Hearing before the subcommittee on health and environment, on the Drug Addiction Treatment Act of 1999, 30 Jul 1999. https:\/\/www.govinfo.gov\/content\/pkg\/CHRG-106hhrg58503\/html\/CHRG-106hhrg58503.htm"},{"key":"2025110102021857000_378.aug16_2.e071467.8","unstructured":"American Society of Addiction Medicine (ASAM) . ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. ASAM, 2020."},{"key":"2025110102021857000_378.aug16_2.e071467.9","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170958"},{"key":"2025110102021857000_378.aug16_2.e071467.10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.1.45"},{"key":"2025110102021857000_378.aug16_2.e071467.11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.1.39"},{"key":"2025110102021857000_378.aug16_2.e071467.12","unstructured":"National Institute for Health and Clinical Excellence. Methadone and buprenorphine for the management of opioid dependence. 2007. https:\/\/www.nice.org.uk\/guidance\/ta114"},{"key":"2025110102021857000_378.aug16_2.e071467.13","unstructured":"UK Departments of Health. Drug misuse and dependence: UK guidelines on clinical management. 2017. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/673978\/clinical_guidelines_2017.pdf"},{"key":"2025110102021857000_378.aug16_2.e071467.14","unstructured":"Department of Health, State of Victoria. Policy for maintenance pharmacotherapy for opioid dependence. 2016. https:\/\/www.vgls.vic.gov.au\/client\/en_AU\/search\/asset\/1293480\/0"},{"key":"2025110102021857000_378.aug16_2.e071467.15","unstructured":"NSW Ministry of Health. NSW clinical guidelines: treatment of opioid dependence\u20132018. 2018. https:\/\/www.health.nsw.gov.au\/aod\/Publications\/nsw-clinical-guidelines-opioid.pdf"},{"key":"2025110102021857000_378.aug16_2.e071467.16","unstructured":"State of Queensland (Queensland Health). Queensland medication-assisted treatment of opioid dependence . 2018. https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0032\/718952\/qld-matod-clin-gdln-2018.pdf"},{"key":"2025110102021857000_378.aug16_2.e071467.17","unstructured":"Pharmascience. Buprenorphine-naloxone product monograph. 2021. https:\/\/web.archive.org\/web\/20211222190531\/https:\/\/pdf.hres.ca\/dpd_pm\/00063411.PDF"},{"key":"2025110102021857000_378.aug16_2.e071467.18","unstructured":"Selby P, Zhang M, Sproule B, et al. Opioid agonist therapy: a synthesis of canadian guidelines for treating opioid use disorder. 2021. https:\/\/www.camh.ca\/-\/media\/files\/professionals\/canadian-opioid-use-disorder-guideline2021-pdf.pdf"},{"key":"2025110102021857000_378.aug16_2.e071467.19","unstructured":"Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. 86 Fed Reg. 22439-22440. April 28, 2021"},{"key":"2025110102021857000_378.aug16_2.e071467.20","unstructured":"FDA. Office-based buprenorphine therapy for opioid dependence: important information for prescribers. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/rems\/BTOD_2020_10_30_Prescriber_Brochure.pdf"},{"key":"2025110102021857000_378.aug16_2.e071467.21","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00535-y"},{"key":"2025110102021857000_378.aug16_2.e071467.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055255"},{"key":"2025110102021857000_378.aug16_2.e071467.23","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12079"},{"key":"2025110102021857000_378.aug16_2.e071467.24","doi-asserted-by":"publisher","DOI":"10.1177\/1049732311432718"},{"key":"2025110102021857000_378.aug16_2.e071467.25","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-020-00795-3"},{"key":"2025110102021857000_378.aug16_2.e071467.26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"2025110102021857000_378.aug16_2.e071467.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.016"},{"key":"2025110102021857000_378.aug16_2.e071467.28","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21090964"},{"key":"2025110102021857000_378.aug16_2.e071467.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2007.01979.x"},{"key":"2025110102021857000_378.aug16_2.e071467.30","doi-asserted-by":"publisher","DOI":"10.1111\/add.12439"},{"key":"2025110102021857000_378.aug16_2.e071467.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.1271"},{"key":"2025110102021857000_378.aug16_2.e071467.32","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29409"},{"key":"2025110102021857000_378.aug16_2.e071467.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.07.005"},{"key":"2025110102021857000_378.aug16_2.e071467.34","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3126"},{"key":"2025110102021857000_378.aug16_2.e071467.35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041"},{"key":"2025110102021857000_378.aug16_2.e071467.36","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.9041"}],"updated-by":[{"DOI":"10.1136\/bmj.o2047","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000}}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj-2022-071467","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj-2022-071467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:02:26Z","timestamp":1761987746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj-2022-071467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":36,"alternative-id":["10.1136\/bmj-2022-071467"],"URL":"https:\/\/doi.org\/10.1136\/bmj-2022-071467","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}